NCT03552718View on ClinicalTrials.gov

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

July 15, 2025

Study Completion Date

December 30, 2025

Conditions
Colorectal CancerBreast CancerHead and Neck Squamous Cell CarcinomaMelanomaNon Small Cell Lung CancerPancreatic CancerLiver Cancer
Interventions
BIOLOGICAL

YE-NEO-001

Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.

Trial Locations (1)

90245

Chan Soon-Shiong Institute for Medicine, El Segundo

All Listed Sponsors
lead

NantBioScience, Inc.

INDUSTRY